ribosomal protein L17 pseudogene 51Genealiases: []
Q-omics provides the consensus-scored RPL17P51 profile across patient tissues and cancer cell-line models. RPL17P51 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL17P51 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RPL17P51 RNA expression shows 3,357 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BRCA, and GBM as cancer lineages where RPL17P51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P51 survival associations across molecular data types. RPL17P51 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P51 RNA expression–survival associations across cancer types. High RPL17P51 expression shows unfavorable associations in UVM, READ, BRCA, THCA, LUAD and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL17P51 RNA expression.
This table summarizes RPL17P51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P51 shows lower tumor expression in BRCA and higher tumor expression in KIRC and LUSC. The BRCA box plot shows higher RPL17P51 RNA expression in normal versus tumor tissue (log2 FC = −0.119, t-test p < 0.001).
This table shows molecular features associated with RPL17P51 in patient tissues and cancer cell lines. In patient samples, RPL17P51 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
